Abstract: A 3D printer includes a gantry configured to move in a plane substantially parallel to a x-y build plane and a print head configured to extrude molten material to print a 3D part in a layer-by-layer process. The 3D printer includes a platen configured to support the part being printed in the layer by layer process and positionable with a primary Z positioner along a z-axis substantially normal to the x-y build plane. The 3D printer includes a local Z positioner moved by the gantry, the local Z positioner comprising a linear motor configured to move the print head in the z-direction and having an operable range of motion extending from a nominal build position at which a nozzle of the print head is positioned in the x-y build plane to a raised position above the x-y build plane.

Abstract: An enzyme detection device (1) for detecting the presence, in a sample, of an enzyme capable of modifying a provided substrate (10). The device (1) comprises a substrate which has a modification region (14) that is sensitive to modification by the enzyme from an unmodified state to a modified state. The device (1) further comprises a substrate recognition molecule (16) which binds the modification region (14) in either the modified or the unmodified state. The modification region 14 of the substrate is preferentially bound by the substrate recognition molecule (16) as compared with the enzyme when mixed. The device further comprises a detectable label (18) coupled to the substrate recognition molecule (17).

Abstract: A product for monitoring the condition of the wound comprising a biologically inert matrix which absorbs wound exudate and one or more reagents on or in the matrix for measuring one or more markers comprised within the wound exudate. A change in the one or more reagents caused by the one or more markers comprised within the wound exudate provides a visual indication of an alteration in the condition of the wound. Companion wound dressings, kits and methods are also provided.

Abstract: Non-enzymatic approaches to measuring glucose are based on the direct oxidation of glucose using unmodified copper metal electrodes. A potential is applied to a copper measurement/working electrode, which potential is monitored by a separate reference electrode and the current within the system is balanced with a counter electrode. The presence of the ionized glucose in the sample can then be determined electrochemically. Disclosed herein are methods, devices, and test systems which utilise this novel approach.

Abstract: Disclosed are compounds of formula (I): which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.

Abstract: Disclosed are compounds of formula (I): which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.

Abstract: Disclosed are compounds of formula (I): which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.

Abstract: Disclosed are compounds of formula (I): which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.

Abstract: Disclosed are compounds of formula (I), which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.

Abstract: A binding screen comprising a gas-porous solid non-water-dispersible carrier, to which has been substantially irreversibly bound a compound having matrix metalloproteinase binding functionality, particularly doxycycline.

Abstract: A peptide clearing agent is provided for clearance of a conjugate of an enzyme and a binding molecule which binds specifically at a target location from a non-target location in a subject. The peptide clearing agent binds the active site of the enzyme. The peptide also binds to the asialoglycoprotein receptor expressed by hepatic cells to facilitate clearance through the liver. The peptide may be glycosylated to facilitate clearance through the liver by binding to hepatic cells expressing an asialoglycoprotein receptor. Typically, the peptide prevents or inhibits enzyme activity upon binding to the enzyme and is not substantially modified by the enzyme activity. The peptide may be based upon the dipeptide amino-naphthoic acid (ANA)-glutamate (GIu) and may comprise the amino acid sequence serine (Ser)-Alanine (Ala)-amino-naphthoic acid (ANA)-glutamate (GIu). In such cases, the enzyme of interest is typically CPG2.

Abstract: An enzyme detection device (1) for detecting the presence, in a sample, of an enzyme capable of modifying a provided substrate (10). The device (1) comprises a substrate which has a modification region (14) that is sensitive to modification by the enzyme from an unmodified state to a modified state. The device (1) further comprises a substrate recognition molecule (16) which binds the modification region (14) in either the modified or the unmodified state. The modification region 14 of the substrate is preferentially bound by the substrate recognition molecule (16) as compared with the enzyme when mixed. The device further comprises a detectable label (18) coupled to the substrate recognition molecule (17).

Abstract: A peptide clearing agent is provided for clearance of a conjugate of an enzyme and a binding molecule which binds specifically at a target location from a non-target location in a subject. The peptide clearing agent binds the active site of the enzyme. The peptide also binds to the asialoglycoprotein receptor expressed by hepatic cells to facilitate clearance through the liver. The peptide may be glycosylated to facilitate clearance through the liver by binding to hepatic cells expressing an asialoglyco-protein receptor. Typically, the peptide prevents or inhibits enzyme activity upon binding to the enzyme and is not substantially modified by the enzyme activity. The peptide may be based upon the dipeptide amino-naphthoic acid (ANA)-glutamate (GIu) and may comprise the amino acid sequence serine (Ser)-Alanine (Ala)-amino-naphthoic acid (ANA)-glutamate (GIu). In such cases, the enzyme of interest is typically CPG2.

Abstract: An enzyme detection product (1) for detecting the presence of an enzyme in a sample. The product (1) comprises: a reaction zone (16) for receiving the sample; a visualization zone (10) for presenting a signal in response to the detection of the activity of the enzyme; and a membrane (11). The membrane (11) is interposable between the reaction zone (16) and the visualization zone (10) and prevents passage from the reaction zone (16) to the visualization zone (10) the components having a size greater than a threshold size. The reaction zone (16) comprises a reactant capable of reacting with the enzyme in order to generate a reaction product having a size less than a threshold size.

Abstract: A binding assay product (1) for detecting the presence of an analyte in a sample comprising a labelling module (5), a label, a capture module (9) and a visualization module (10). The labelling module (5) comprises a first binding component capable of binding the analyte. The label is connectable to the first binding component. The capture module (9) comprises a second binding component capable of binding the analyte. The visualization module (10) is for detecting the first binding component connected to the label and bound to the second binding component via the analyte. The labelling module and the capture module comprise a fluid conducting medium in which the binding components are embedded. The labelling module (5), the capture module (9) and the visualization module (10) together define a flow path along which the sample is capable of flowing.

Abstract: An enzyme detection device (1) for detecting the presence, in a sample, of an enzyme capable of modifying a provided substrate (10). The device (1) comprises a substrate which has a modification region (14) that is sensitive to modification by the enzyme from an unmodified state to a modified state. The device (1) further comprises a substrate recognition molecule (16) which binds the modification region (14) in either the modified or the unmodified state. The modification region 14 of the substrate is preferentially bound by the substrate recognition molecule (16) as compared with the enzyme when mixed. The device further comprises a detectable label (18) coupled to the substrate recognition molecule (17).

Abstract: A docking station for use in combined imaging of a tissue wound and a test substrate comprising a sample from a tissue wound, the docking station comprises means for connecting the station to a processor which processes and stores the images. The docking station also incorporates means for receiving a test substrate comprising a sample from a tissue wound. The docking station also includes means for docking a sensor in the station, which sensor detects the light reflected from an illuminated tissue wound, such that an image of the tissue wound can be communicated from the station to the processor. The means for docking is arranged such that when the sensor is docked in the station and the test substrate is received by the docking station, the sensor is positioned to detect the intensity of reflected light from the test substrate and communicates the detected intensity of reflected light to the processor to thus permit combined imaging of the tissue wound and test substrate.

Abstract: Disclosed are compounds of formula (I), which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.

Abstract: A method of detecting a protease in a sample. The method comprises providing an analyte degradable by the protease. The analyte is contacted with the sample. The degradation products of the analyte or the residual undegraded analyte is detected in a binding assay.

Abstract: A skin dressing comprises a first dressing component (16) carrying oxidoreductase enzyme in dried condition; and a second dressing component (18) carrying a source of water, such that when the first and second dressing components are placed in fluid communication with each other, water migrates from the second component towards the first comportent and acts to hydrate enzyme carried by the first component, at least at the surface of the first component. The dressing components are kept separate before use, e.g. being sealed in separate sterile, water-impervious packages such as laminated aluminum foil pouches. In use of the dressing, the second dressing component is located on the skin of a human or animal, e.g. over a wound to be treated or on a region of skin to be treated for cosmetic or therapeutic purposes such as for treatment of acne or other skin conditions. The first dressing component is placed on top of the second component in fluid communication therewith.